Stanford Neuro-Immuno-Oncology Program Clinical Trials

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma (DMG)
Sponsor: Crystal Mackall, MD
Principal Investigator: Michelle Monje, MD, PhD
Description: This is an open label, non-randomized, single site Phase 1 study to test the manufacturing feasibility and safety of administration of GD2 CAR T into the central nervous system of pediatric and adult subjects with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) using a rolling-6 escalation design
ClinicalTrials.gov Identifier: NCT04196413
Study Status: Enrolling
Contact: GD2CART@stanfordchildrens.org or 650-497-7533

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Sponsor: Crystal Mackall, MD
Principal Investigator: Reena Thomas, MD, PhD
Description: This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design
ClinicalTrials.gov Identifier: NCT05474378
Study Status: Enrolling
Contact: lewis.naya@stanford.edu or 650-725-0379